The Australian Dementia Network (Adnet): Bringing Together Australia’s Dementia Stakeholders

Harmonizing neuropsychological test data across prospective studies

R Shishegar, JD Doecke, YY Lim, P Bourgeat, V Dore, B Tallapragada, SM Laws, T Porter, S Burnham, A Feizpour, A Gillman, M Weiner, J Hassenstab, CC Rowe, VL Villemagne, CL Masters, J Fripp, H Sohrabi, P Maruff

2026-02-01

INTRODUCTION: Alzheimer's disease (AD) research relies on large datasets and advanced statistical models. However, individual popu..

Alzheimer’s disease biological PET staging using plasma p217 tau

A Feizpour, V Doré, N Krishnadas, P Bourgeat, JD Doecke, ZS Saad, G Triana-Baltzer, SM Laws, R Shishegar, K Huang, C Fowler, L Ward, CL Masters, J Fripp, HC Kolb, VL Villemagne, CC Rowe

2025-12-01

Background: Plasma phospho-tau biomarkers, such as p217+tau, excel at identifying Alzheimer’s disease (AD) neuropathology. However..

Altered Striatal Functional Gradients in Obsessive-Compulsive Disorder

L Webb, LJ Hearne, YE Tian, A Zalesky, C Robinson, CV Hall, S Sonkusare, B Burgher, M Breakspear, GM Meyer, A Horn, S Naze, P Mosley, L Cocchi

2025-11-01

Background Obsessive-compulsive disorder (OCD) is associated with functional alterations in how the striatum interacts with the re..

Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials

R Ossenkoppele, G Salvadó, S Janelidze, A Pichet Binette, D Bali, L Karlsson, S Palmqvist, N Mattsson-Carlgren, E Stomrud, J Therriault, N Rahmouni, P Rosa-Neto, EM Coomans, E van de Giessen, WM van der Flier, CE Teunissen, EM Jonaitis, SC Johnson, S Villeneuve, TLS Benzinger

2025-05-01

Plasma p-tau217 and tau positron emission tomography (PET) are strong prognostic biomarkers in Alzheimer’s disease (AD), but their..

Implementation of cognition-oriented treatments (COTs) for older adults in Australian memory and cognition clinics: development and pilot evaluation of a clinician training toolkit

A Bahar-Fuchs, C Chesser, L Mowszowski, KE Pike, A Lee, I Mehrani, AM Hutchinson, S Naismith

2025-01-01

The uptake of Cognition-Oriented Treatments (COTs) has remained slow in memory and cognition clinics in Australia despite strong r..

Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform

A Feizpour, JD Doecke, V Doré, N Krishnadas, K Huang, P Bourgeat, SM Laws, C Fowler, J Robertson, L Mackintosh, S Ayton, R Martins, SR Rainey-Smith, K Taddei, L Ward, E Stage, AW Bannon, CL Masters, J Fripp, VL Villemagne

2024-11-01

Background: Plasma phospho-tau 217 (pTau217) assays can accurately detect Alzheimer's disease (AD) pathology, but clinical applica..

Inter-scanner Aβ-PET harmonization using barrel phantom spatial resolution matching

Gihan P Ruwanpathirana, Robert C Williams, Colin L Masters, Christopher C Rowe, Leigh A Johnston, Catherine E Davey

2024-01-01

INTRODUCTION: The standardized uptake value ratio (SUVR) is used to measure amyloid beta–positron emission tomography (Aβ-PET) upt..

Tackling Dementia Together via The Australian Dementia Network (ADNeT): A Summary of Initiatives, Progress and Plans

SL Naismith, JC Michaelian, C Santos, I Mehrani, J Robertson, K Wallis, X Lin, SA Ward, R Martins, CL Masters, M Breakspear, S Ahern, J Fripp, PR Schofield, PS Sachdev, CC Rowe

2023-11-21

In 2018, the Australian Dementia Network (ADNeT) was established to bring together Australia’s leading dementia researchers, peopl..

CenTauR: Toward a universal scale and masks for standardizing tau imaging studies

VL Villemagne, A Leuzy, SS Bohorquez, S Bullich, H Shimada, CC Rowe, P Bourgeat, B Lopresti, K Huang, N Krishnadas, J Fripp, Y Takado, A Gogola, D Minhas, R Weimer, M Higuchi, A Stephens, O Hansson, V Doré

2023-07-01

INTRODUCTION: Recently, an increasing number of tau tracers have become available. There is a need to standardize quantitative tau..

Functional re-organization of hippocampal-cortical gradients during naturalistic memory processes

L Borne, Y Tian, MK Lupton, JN van der Meer, J Jeganathan, B Paton, N Koussis, CC Guo, GA Robinson, J Fripp, A Zalesky, M Breakspear

2023-05-01

The functional organization of the hippocampus mirrors that of the cortex, changing smoothly along connectivity gradients and abru..

Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality

YE Tian, V Cropley, AB Maier, NT Lautenschlager, M Breakspear, A Zalesky

2023-05-01

Biological aging of human organ systems reflects the interplay of age, chronic disease, lifestyle and genetic risk. Using longitud..

Characterising Australian memory clinics: current practice and service needs informing national service guidelines

SL Naismith, JC Michaelian, LF Low, V Arsenova, I Mehrani, K Fyfe, NA Kochan, SE Kurrle, C Rowe, PS Sachdev

2022-12-01

Background: Memory clinics (MCs) play a key role in accurate and timely diagnoses and treatment of dementia and mild cognitive imp..

Plasma p217 tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum

V Doré, JD Doecke, ZS Saad, G Triana-Baltzer, R Slemmon, N Krishnadas, P Bourgeat, K Huang, S Burnham, C Fowler, SR Rainey-Smith, AI Bush, L Ward, J Robertson, RN Martins, CL Masters, VL Villemagne, J Fripp, HC Kolb, CC Rowe

2022-01-01

Introduction: We evaluated a new Simoa plasma assay for phosphorylated tau (P-tau) at aa217 enhanced by additional p-tau sites (p2..

Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease

N Krishnadas, K Huang, SA Schultz, V Doré, P Bourgeat, AMY Goh, F Lamb, S Bozinovski, SC Burnham, JS Robertson, SM Laws, P Maruff, CL Masters, VL Villemagne, CC Rowe

2022-01-01

Background: In Alzheimer's disease, heterogeneity has been observed in the postmortem distribution of tau neurofibrillary tangles...

Relationship between amyloid and tau levels and its impact on tau spreading

V Doré, N Krishnadas, P Bourgeat, K Huang, S Li, S Burnham, CL Masters, J Fripp, VL Villemagne, CC Rowe

2021-07-01

Purpose: Previous studies have shown that Aβ-amyloid (Aβ) likely promotes tau to spread beyond the medial temporal lobe. However, ..

Optimising participation of persons with cognitive impairment in a national dementia registry: challenges and solutions

X Lin, K Wallis, S Ahern, H Brodaty, C Rowe, B Kain, S Lambourne, J McNeil, SA Ward

2021-06-01

Clinical quality registries are increasingly utilised to monitor and improve healthcare quality. Opt-out consent is recommended to..

Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals

LM Van Der Kall, T Truong, SC Burnham, V Doré, RS Mulligan, S Bozinovski, F Lamb, P Bourgeat, J Fripp, S Schultz, YY Lim, SM Laws, D Ames, C Fowler, SR Rainey-Smith, RN Martins, O Salvado, J Robertson, P Maruff, CL Masters

2021-02-02

ObjectiveTo determine the effect of β-amyloid (Aβ) level on progression risk to mild cognitive impairment (MCI) or dementia and lo..

The protocol of a clinical quality registry for dementia and mild cognitive impairment (MCI): The Australian dementia network (ADNeT) Registry

X Lin, K Wallis, SA Ward, H Brodaty, PS Sachdev, SL Naismith, K Krysinska, J McNeil, CC Rowe, S Ahern

2020-09-07

Background: Dementia was identified as a priority area for the development of a Clinical Quality Registry (CQR) in Australia in 20..